Administration of anti-HER2 and satisfaction of patients treated for breast cancer
CONCLUSION: SC administration of anti-HER2 under the supervision of an APN has advantages for the patient, resulting in greatest satisfaction and improved patient QOL, preferably in HOD.PMID:38480056 | DOI:10.1016/j.bulcan.2024.01.006 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 13, 2024 Category: Cancer & Oncology Authors: Sol ène Pallaro Marion Bigas Sophie Leobon Kim-Arthur Baffert Cl émentine Peyramaure Laurence Dubest Laurence Venat Ga ëlle Maillan Élise Deluche Source Type: research
Prevention, diagnosis and management of osteoradionecrosis: Where do we stand?
The objective of this literature review was to provide an overview of the management of ORN and to determine the key points that would make it possible to improve patient care. The diagnosis of ORN requires to eliminate tumor recurrence then is based on clinical arguments and imaging by CT or Cone Beam evolving in a chronic mode (more than 3-6 months). The harmonization of its classifications aims to offer comprehensive and multidisciplinary care as early as possible. Primary prevention is based on pre-therapeutic oral and dental preparation, then associated with fluoroprophylaxis if salivary recovery is insufficient and r...
Source: Bulletin du Cancer - March 13, 2024 Category: Cancer & Oncology Authors: Florent Carsuzaa M élanie Dore Sabah Falek Gr égory Delpon Julien Drouet Juliette Thariat Source Type: research
Pediatric aphereses (workshop SFGM-TC)
Bull Cancer. 2024 Mar 12:S0007-4551(24)00042-0. doi: 10.1016/j.bulcan.2023.12.008. Online ahead of print.ABSTRACTPractice of pediatric aphereses - in particular when caring for low-weight children - differs from the practice of adult aphereses, since pediatric aphereses represent low numbers of procedures, which has practical implications in terms of practical training and retraining for involved healthcare personnel, as needed for habilitation and validation of ongoing competencies. A specific training is mandatory in order to ensure both the child and the staff safety during and after collection, as well as ensure high q...
Source: Bulletin du Cancer - March 13, 2024 Category: Cancer & Oncology Authors: Christian Chabannon Malek Benakli Kamelia Alexandrova Carole Coze Jean-Hughes Dalle Christine Giraud Phuong Huynh Tarik Kanouni Justyna Kanold Isabelle Lesieur Aur élie Levavasseur Ibrahim Yakoub-Agha Etienne Baudoux Source Type: research
Administration of anti-HER2 and satisfaction of patients treated for breast cancer
CONCLUSION: SC administration of anti-HER2 under the supervision of an APN has advantages for the patient, resulting in greatest satisfaction and improved patient QOL, preferably in HOD.PMID:38480056 | DOI:10.1016/j.bulcan.2024.01.006 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 13, 2024 Category: Cancer & Oncology Authors: Sol ène Pallaro Marion Bigas Sophie Leobon Kim-Arthur Baffert Cl émentine Peyramaure Laurence Dubest Laurence Venat Ga ëlle Maillan Élise Deluche Source Type: research
Prevention, diagnosis and management of osteoradionecrosis: Where do we stand?
The objective of this literature review was to provide an overview of the management of ORN and to determine the key points that would make it possible to improve patient care. The diagnosis of ORN requires to eliminate tumor recurrence then is based on clinical arguments and imaging by CT or Cone Beam evolving in a chronic mode (more than 3-6 months). The harmonization of its classifications aims to offer comprehensive and multidisciplinary care as early as possible. Primary prevention is based on pre-therapeutic oral and dental preparation, then associated with fluoroprophylaxis if salivary recovery is insufficient and r...
Source: Bulletin du Cancer - March 13, 2024 Category: Cancer & Oncology Authors: Florent Carsuzaa M élanie Dore Sabah Falek Gr égory Delpon Julien Drouet Juliette Thariat Source Type: research
Dabrafenib and trametinib-BRAF V600E mutated pediatric gliomas
Bull Cancer. 2024 Mar 11:S0007-4551(24)00073-0. doi: 10.1016/j.bulcan.2024.01.005. Online ahead of print.NO ABSTRACTPMID:38471994 | DOI:10.1016/j.bulcan.2024.01.005 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 12, 2024 Category: Cancer & Oncology Authors: Olivia Giorgis Fran çois Doz Source Type: research
Pembrolizumab in adjuvant therapy in non-small cell lung cancers
Bull Cancer. 2024 Mar 11:S0007-4551(24)00047-X. doi: 10.1016/j.bulcan.2023.12.012. Online ahead of print.NO ABSTRACTPMID:38471995 | DOI:10.1016/j.bulcan.2023.12.012 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 12, 2024 Category: Cancer & Oncology Authors: Antoine Lef èvre Claire Tissot Source Type: research
Dabrafenib and trametinib-BRAF V600E mutated pediatric gliomas
Bull Cancer. 2024 Mar 11:S0007-4551(24)00073-0. doi: 10.1016/j.bulcan.2024.01.005. Online ahead of print.NO ABSTRACTPMID:38471994 | DOI:10.1016/j.bulcan.2024.01.005 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 12, 2024 Category: Cancer & Oncology Authors: Olivia Giorgis Fran çois Doz Source Type: research
Pembrolizumab in adjuvant therapy in non-small cell lung cancers
Bull Cancer. 2024 Mar 11:S0007-4551(24)00047-X. doi: 10.1016/j.bulcan.2023.12.012. Online ahead of print.NO ABSTRACTPMID:38471995 | DOI:10.1016/j.bulcan.2023.12.012 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 12, 2024 Category: Cancer & Oncology Authors: Antoine Lef èvre Claire Tissot Source Type: research
Pembrolizumab+chemotherapy as first-line treatment in patients with HER negative advanced oesogastric adenocarcinoma
Bull Cancer. 2024 Mar 7:S0007-4551(24)00072-9. doi: 10.1016/j.bulcan.2024.01.004. Online ahead of print.NO ABSTRACTPMID:38458924 | DOI:10.1016/j.bulcan.2024.01.004 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 8, 2024 Category: Cancer & Oncology Authors: Martin Duval Aziz Zaanan Source Type: research
Talquetamab - multiple myeloma after at least three prior lines of therapy
Bull Cancer. 2024 Mar 7:S0007-4551(24)00049-3. doi: 10.1016/j.bulcan.2023.12.014. Online ahead of print.NO ABSTRACTPMID:38458925 | DOI:10.1016/j.bulcan.2023.12.014 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 8, 2024 Category: Cancer & Oncology Authors: Thomas Fatrara Emilie Chalayer Source Type: research
Sacituzumab-govitecan in hormone-receptor positive/HER2-negative advanced breast cancer
Bull Cancer. 2024 Mar 7:S0007-4551(24)00046-8. doi: 10.1016/j.bulcan.2023.12.011. Online ahead of print.NO ABSTRACTPMID:38458926 | DOI:10.1016/j.bulcan.2023.12.011 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 8, 2024 Category: Cancer & Oncology Authors: Hanna Besnainou Luc Cabel Source Type: research
PAL-PRAT study: Healthcare workers' knowledge and perception of palliative practices in a Cancer Center
DISCUSSION: This survey underlines the importance of training and support for the professionals caring for patients in palliative situation and their relatives in France.PMID:38458927 | DOI:10.1016/j.bulcan.2023.12.009 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 8, 2024 Category: Cancer & Oncology Authors: Marie Locatelli C écile Flahault Nicolas Roche Christine Mateus Fran çois Blot None Lucile Montalescot Jean-Bernard Le Provost L éonor Fasse Source Type: research
Barriers and facilitators to physical activity in oncology in Seine-Saint-Denis: A qualitative study using the socio-ecological approach
DISCUSSION: A diversity of representations, combinations of factors, and experiences are described. Getting people with cancer to engage in and maintain long-term physical activity is a complex task, requiring multidisciplinary action on all socio-ecological factors.PMID:38458928 | DOI:10.1016/j.bulcan.2023.12.017 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 8, 2024 Category: Cancer & Oncology Authors: C édric Sarreboubee Albane Aumaitre Lazhar Labiadh Aude-Marie Foucaut Source Type: research
Pembrolizumab+chemotherapy as first-line treatment in patients with HER negative advanced oesogastric adenocarcinoma
Bull Cancer. 2024 Mar 7:S0007-4551(24)00072-9. doi: 10.1016/j.bulcan.2024.01.004. Online ahead of print.NO ABSTRACTPMID:38458924 | DOI:10.1016/j.bulcan.2024.01.004 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 8, 2024 Category: Cancer & Oncology Authors: Martin Duval Aziz Zaanan Source Type: research
